Tofacitinib
Treatment for Inflammatory Bowel Disease
Typical Dosage: 5-10 mg twice daily
Effectiveness
72%
Safety Score
48%
Clinical Trials
40
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
48
DangerousModerateSafe
Treatment Details
Dosage Range
5-10 mg twice daily
Time to Effect
2-8 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
40(Treat 40 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$40,000
Monitoring:$4,000
Side Effect Mgmt:$2,500
Total Annual:$46,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$250,000/QALY
QALYs Gained
0.25
Outcome-Based Costs
Cost per Responder
$84,545
Cost per Remission
$258,333
Comparison vs Azathioprine
Cost Difference
+$45,000/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Tofacitinib Outcomes
for Inflammatory Bowel Disease
Efficacy Outcomes
Overall Effectiveness
+72%
Response Rate
+55%
Remission Rate
+18%
Common Side Effects
Nasopharyngitis
+15%
Herpes Zoster
+7%
Upper respiratory tract infection
+10%
Serious infections
+2.5%
MACE/Malignancy
+1.5%
Sources:
Active Clinical Trials
10 active trials recruiting for Tofacitinib in Inflammatory Bowel Disease
Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications
NCT05104723ENROLLING BY INVITATIONPHASE1, PHASE2
20 participants
INTERVENTIONAL
Bethesda, United States
Started: Aug 12, 2022
TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS
NCT06625450NOT YET RECRUITINGPHASE4
75 participants
INTERVENTIONAL
Started: Oct 1, 2024
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
NCT04624230RECRUITINGPHASE3
120 participants
INTERVENTIONAL
Los Angeles, United States +76 more
Started: Aug 12, 2021
Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis
NCT04424303RECRUITING
280 participants
OBSERVATIONAL
Amiens, France +37 more
Started: Dec 4, 2020
Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden
NCT04338204RECRUITING
120 participants
OBSERVATIONAL
Alingsås, Sweden +16 more
Started: Sep 14, 2020
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT06095128RECRUITINGPHASE4
65 participants
INTERVENTIONAL
Dothan, United States +49 more
Started: Jun 12, 2024
Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis
NCT05112263NOT YET RECRUITINGNA
96 participants
INTERVENTIONAL
Started: Jul 1, 2023
Prediction Model for Response to Biologics and Small Molecular Agent for UC
NCT05186623RECRUITING
300 participants
OBSERVATIONAL
Seoul, South Korea
Started: Feb 5, 2022
COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)
NCT07198113NOT YET RECRUITING
1.1K participants
OBSERVATIONAL
Chapel Hill, United States +1 more
Started: Nov 1, 2025
Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events
NCT05313620RECRUITINGPHASE4
30 participants
INTERVENTIONAL
Madrid, Spain
Started: Apr 1, 2022
Completed Clinical Trials
6 completed trials for Tofacitinib in Inflammatory Bowel Disease
Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease
NCT03885713COMPLETEDPHASE4
180 participants
INTERVENTIONAL
Alicante, Spain +20 more
Started: Sep 10, 2019
Retrospective Observational Comparison Study Between Ustekinumab and Tofacitinib as Third Line Therapy in a Multicenter Cohort of Patients With Refractory Ulcerative Colitis.
NCT05728008COMPLETED
100 participants
OBSERVATIONAL
Milan, Italy
Started: Apr 5, 2022
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis
NCT01465763COMPLETEDPHASE3
614 participants
INTERVENTIONAL
Mobile, United States +177 more
Started: Apr 1, 2012
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis
NCT01458951COMPLETEDPHASE3
547 participants
INTERVENTIONAL
Tucson, United States +181 more
Started: Jun 1, 2012
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
NCT01393899COMPLETEDPHASE2
180 participants
INTERVENTIONAL
Anaheim, United States +90 more
Started: Mar 1, 2012
Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD)
NCT04852666COMPLETED
465 participants
OBSERVATIONAL
New York, United States +1 more
Started: Jul 25, 2019
Showing 20 of 40 total trials